Skip to Content

The promise and peril of engineering biology

reshma_shetty

Moderna’s Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. The key, Shetty says, is propelling progress but not at the expense of principles. Engineering genes is a high-stakes pursuit, so Ginkgo is trying to pair the ambition of Silicon Valley with a “higher level of care.”

“Our mission is to make biology easier to engineer.”

— Reshma Shetty
About the guest:
reshma_shetty

Reshma Shetty, co founder and COO of Ginkgo Bioworks, the breakthrough synthetic biology company.

About the host:
bob_safian

Bob Safian is the host of Masters of Scale: Rapid Response, and the editor-at-large for Masters of Scale. He’s the founder of The Flux Group, a media, insights, and strategic advisory firm. He was previously editor-in-chief of Fast Company, where he won the National Magazine Award for Magazine of the Year in 2014.

Transcript of Masters of Scale: The promise and peril of engineering biology
Masters of Scale’s mission is to democratize entrepreneurship. Launched in 2017 as a weekly podcast featuring Reid Hoffman, we’re now two weekly podcasts — Masters of Scale with Reid Hoffman, and Masters of Scale: Rapid Response, hosted by Bob Safian — as well as an award-winning daily learning app, a best-selling book, virtual and live events, and more, serving a global community of founders, funders, and leaders looking to innovate at scale.
Sign up for our weekly newsletter